Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023
26 oct. 2023 08h30 HE
|
Ascendis Pharma
— Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination...
Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023
16 oct. 2023 16h01 HE
|
Ascendis Pharma
— 52-week results from the Phase 3 PaTHway Trial showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer...
Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting
02 oct. 2023 08h00 HE
|
Ascendis Pharma
– At Week 26, 81% of patients in Phase 3 PaTHway Trial with chronic post-surgical hypoparathyroidism, the most common cause of this disease, achieved independence from conventional therapy while...
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency
23 sept. 2023 07h00 HE
|
Ascendis Pharma
- The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit ...
Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency
15 sept. 2023 08h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the launch in Germany of SKYTROFA® (lonapegsomatropin), its growth hormone approved in the...
Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism
14 sept. 2023 12h22 HE
|
Ascendis Pharma
- Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024 COPENHAGEN, Denmark, Sept. 14, 2023...
Ascendis Pharma Reports Second Quarter 2023 Financial Results
05 sept. 2023 16h03 HE
|
Ascendis Pharma
Expect to resubmit NDA to FDA for TransCon™ PTH in October 2023; EC decision on MAA for TransCon PTH expected during the fourth quarter of 2023U.S. and EU regulatory authorities endorsed ApproaCH as a...
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
05 sept. 2023 16h01 HE
|
Ascendis Pharma
- Proceeds to support continued development and commercialization of Endocrine Rare Disease products, and general corporate purposes COPENHAGEN, Denmark and NEW YORK, Sept. 05, 2023 (GLOBE...
New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism
05 sept. 2023 16h01 HE
|
Ascendis Pharma
- Approximately 50% of Phase 3 PaTHway Trial patients with eGFR < 60 mL/min/1.73m2, the threshold for kidney dysfunction, receiving TransCon PTH experienced eGFR improvement to above 60...
Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
24 août 2023 08h30 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice...